

# ABSORBED-DOSE SPECIFICATION IN NUCLEAR MEDICINE

## CONTENTS

THE INTERNATIONAL COMMISSION ON RADIATION UNITS AND MEASUREMENTS . . . . .	3
CONTENTS . . . . .	5
ABSTRACT . . . . .	9
PREFACE . . . . .	11
EXECUTIVE SUMMARY . . . . .	13
1 INTRODUCTION . . . . .	15
1.1 Rationale for the report . . . . .	15
1.2 Interest of the nuclear medicine community in revised guidelines . . . . .	16
1.3 History of absorbed-dose specification in nuclear medicine . . . . .	16
1.4 Outline of the report . . . . .	16
2 BIOLOGICAL CONSIDERATIONS . . . . .	17
2.1 Introduction . . . . .	17
2.2 Biological endpoints . . . . .	17
2.2.1 Biomolecular lesions . . . . .	17
2.2.1.1 DNA damage and repair . . . . .	17
2.2.1.2 Chromosomal aberrations . . . . .	17
2.2.2 Germ-cell damage . . . . .	18
2.2.2.1 Hereditary genetic effects . . . . .	18
2.2.2.2 Spermatogenesis and oogenesis . . . . .	19
2.2.3 Developmental defects . . . . .	19
2.2.4 Carcinogenesis . . . . .	20
2.2.4.1 Cellular transformation . . . . .	20
2.2.4.2 Mutagenesis . . . . .	20
2.2.4.3 Animal tumours . . . . .	21
2.2.4.4 Human tumours . . . . .	21
2.2.5 Response to therapy . . . . .	22
2.2.5.1 Cellular responses: clonal survival, repair, apoptosis, division delay, redistribution, reoxygenation and regeneration . . . . .	22
2.2.5.2 Normal tissue response . . . . .	23
2.2.5.3 Tumour response . . . . .	25

ABSORBED-DOSE SPECIFICATION IN NUCLEAR MEDICINE

<b>2.3</b>	<b>Biological factors in the selection of radionuclides</b>	26
2.3.1	<i>Photon emitters</i>	26
2.3.2	<i>Beta particle emitters</i>	26
2.3.3	<i>Alpha particle emitters</i>	27
2.3.4	<i>Auger electron emitters</i>	28
<b>2.4</b>	<b>Tumour and normal tissue dose-response</b>	28
2.4.1	<i>Radiobiological principles for varying dose rate, non-uniform dose distribution, and different relative biological effectiveness</i>	28
2.4.1.1	<i>Dose rate</i>	28
2.4.1.2	<i>Non-uniformity</i>	29
2.4.1.3	<i>Biological weighting factors</i>	30
2.4.2	<i>Dose response for radionuclide therapy</i>	30
2.4.3	<i>Comparison of animal tumour and normal tissue responses to radionuclide therapy and external-beam therapy</i>	31
2.4.4	<i>Probability of tumour control versus normal tissue complications</i>	32
2.4.4.1	<i>Normal-tissue complication probability</i>	32
2.4.4.2	<i>Tumour control probability</i>	32
2.4.4.3	<i>Series and parallel architecture models for normal-tissue complication probability and tumour control probability</i>	32
2.4.4.4	<i>Implications for internal emitter normal-tissue complication probability in liver</i>	33
2.4.5	<i>Dose-volume histogram characteristics and figure-of-merit analysis</i>	33
<b>3</b>	<b>THE MIRD SCHEMA</b>	35
<b>3.1</b>	<b>Introduction</b>	35
<b>3.2</b>	<b>Basic concepts</b>	35
3.2.1	<i>Absorbed-dose rate</i>	35
3.2.2	<i>Absorbed fraction</i>	35
3.2.3	<i>Mean energy emitted per nuclear transition</i>	35
3.2.4	<i>Absorbed dose</i>	35
3.2.5	<i>Cumulated activity</i>	36
3.2.6	<i>Specific absorbed fraction</i>	36
3.2.7	<i>Mean absorbed dose per unit cumulated activity</i>	36
3.2.8	<i>Residence time of cumulated activity</i>	36
<b>3.3</b>	<b>Formulae</b>	36
<b>3.4</b>	<b>Calculation of cumulated activity</b>	38
<b>3.5</b>	<b>Strengths and limitations of the MIRD schema</b>	38
<b>3.6</b>	<b>Generalisation of formulae for time-dependent mass</b>	39
<b>4</b>	<b>DOSIMETRIC CONSIDERATIONS FOR NON-UNIFORM DISTRIBUTIONS OF RADIOACTIVITY</b>	41
<b>4.1</b>	<b>Introduction</b>	41
<b>4.2</b>	<b>Basic aspects of radionuclide decay and dosimetry</b>	42
4.2.1	<i>Radionuclide decay and emission characteristics</i>	42
4.2.1.1	<i>Beta decay</i>	42

## CONTENTS

4.2.1.2	Alpha decay. . . . .	43
4.2.1.3	Isomeric transitions producing photons . . . . .	43
4.2.2	Definitions of self-dose, cross-dose, sources and targets . . . . .	43
<b>4.3</b>	<b>Spatial distribution of radioactivity . . . . .</b>	<b>44</b>
4.3.1	Spatial distribution of radioactivity in organs and tissues . . . . .	44
4.3.1.1	Distribution among organs . . . . .	44
4.3.1.2	Distribution in tissue elements within organs . . . . .	44
4.3.1.3	Cellular distribution . . . . .	46
4.3.1.4	Subcellular distribution . . . . .	47
4.3.2	Spatial distribution of radioactivity in tumour tissues . . . . .	48
4.3.2.1	Distribution in primary and metastatic tumours . . . . .	48
4.3.2.2	Distribution at the cellular level in micrometastases . . . . .	50
4.3.2.3	Subcellular distribution . . . . .	50
<b>4.4</b>	<b>Implications of non-uniformity for dose distribution . . . . .</b>	<b>51</b>
4.4.1	Photons. . . . .	51
4.4.1.1	Organ level . . . . .	51
4.4.1.2	Tissue-element level. . . . .	54
4.4.1.3	Cellular and subcellular levels. . . . .	55
4.4.2	Beta particles . . . . .	55
4.4.2.1	Organ level . . . . .	55
4.4.2.2	Tissue-element level. . . . .	56
4.4.2.3	Cellular and subcellular levels. . . . .	58
4.4.3	Alpha particles. . . . .	59
4.4.3.1	Organ level . . . . .	59
4.4.3.2	Tissue-element level. . . . .	60
4.4.3.3	Cellular and subcellular levels. . . . .	60
4.4.4	Auger and Coster-Kronig electrons . . . . .	62
4.4.4.1	Organ level . . . . .	63
4.4.4.2	Tissue-element level. . . . .	63
4.4.4.3	Cellular and subcellular levels. . . . .	63
<b>4.5</b>	<b>Dose-volume histograms. . . . .</b>	<b>64</b>
4.5.1	Description of a dose-volume histogram. . . . .	64
4.5.2	Calculation of a dose-volume histogram . . . . .	64
4.5.3	Implementation of dose-volume histograms in radionuclide therapy . . . . .	65
<b>4.6</b>	<b>Temporal considerations for absorbed-dose non-uniformity . . . . .</b>	<b>65</b>
4.6.1	Temporal quantities relevant to activity distribution . . . . .	65
4.6.2	Pharmacokinetics of a radionuclide with and without a carrier . . . . .	66
4.6.2.1	Uptake, retention and clearance phases . . . . .	66
4.6.2.2	Size, charge and amount of carrier . . . . .	67
4.6.2.3	Route and timing of administration . . . . .	67
4.6.2.4	Effects of $T_b$ and $T$ on distribution over time . . . . .	68
4.6.3	Temporal changes in absorbed fraction and $S$ value . . . . .	68
4.6.3.1	Structural compartmentalisation. . . . .	68
4.6.3.2	Proximity to arterial and venous supply . . . . .	69

ABSORBED-DOSE SPECIFICATION IN NUCLEAR MEDICINE

4.6.4	<i>Methods of detection</i> . . . . .	69
4.6.4.1	<i>Selection of sampling-time intervals</i> . . . . .	69
4.6.4.2	<i>Matching the method with the information desired</i> . . . . .	69
4.7	<b>Extrapolation of animal data to humans</b> . . . . .	70
5	<b>TECHNIQUES AND PROCEDURES</b> . . . . .	71
5.1	<b>Introduction</b> . . . . .	71
5.2	<b>Image based quantification of time-variant activity distributions</b> . . . . .	71
5.2.1	<i>Planar methods</i> . . . . .	71
5.2.2	<i>Emission tomographic methods</i> . . . . .	72
5.2.3	<i>Serial image acquisitions</i> . . . . .	73
5.2.4	<i>Validation of computed activity distributions</i> . . . . .	73
5.3	<b>Image based determination of organ and tissue-element masses</b> . . . . .	74
5.3.1	<i>Regions of interest and volumes in emission computed tomography</i> . . . . .	74
5.3.2	<i>Image correlation and registration</i> . . . . .	75
5.3.2.1	<i>Registration basis</i> . . . . .	75
5.3.2.2	<i>Permitted transforms</i> . . . . .	75
5.3.2.3	<i>Optimisation procedure</i> . . . . .	76
5.3.3	<i>Histological variation</i> . . . . .	76
5.4	<b>Patient specific dose computations</b> . . . . .	76
5.4.1	<i>Monte Carlo method</i> . . . . .	76
5.4.1.1	<i>Monte Carlo dosimetry</i> . . . . .	77
5.4.1.2	<i>Individualised S values</i> . . . . .	77
5.4.1.3	<i>Convolution methods</i> . . . . .	77
5.4.2	<i>Application of individualised dosimetry</i> . . . . .	77
5.5	<b>Small-scale dosimetry</b> . . . . .	78
5.5.1	<i>Autoradiographic measurements</i> . . . . .	78
5.5.2	<i>Autoradiography and absorbed-dose determination at the cellular level</i> . . . . .	80
5.5.3	<i>Use of autoradiographic data in dosimetry</i> . . . . .	80
5.5.4	<i>Comparison with macrodosimetry</i> . . . . .	81
5.5.5	<i>High-resolution imaging of animals</i> . . . . .	81
5.6	<b>Measurement of absorbed dose and comparison with calculations</b> . . . . .	82
5.6.1	<i>Dosemeters in nuclear medicine</i> . . . . .	82
5.6.2	<i>Absorbed-dose measurements in phantoms</i> . . . . .	83
5.6.3	<i>Absorbed-dose measurements in animals</i> . . . . .	83
5.6.4	<i>Clinical absorbed-dose measurements</i> . . . . .	84
5.6.5	<i>Software and physical phantoms for dosimetry</i> . . . . .	85
APPENDIX 1: THE CONCEPT OF BIOLOGICALLY EQUAL EFFECTIVE DOSE . . . . .		87
APPENDIX 2: DECAY SCHEMES . . . . .		89
REFERENCES . . . . .		91